NextPlat (NXPL) Other Accumulated Expenses (2018 - 2026)
NextPlat's (NXPL) quarterly Other Accumulated Expenses came in at $586000.0 in Q2 2026, up 105.61% year-over-year from $285000.0 in Q2 2025, and up 187.25% quarter-over-quarter from $204000.0 in Q1 2026.
Analysis
NextPlat (NXPL) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Other Accumulated Expenses for 9 consecutive years, with $586000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Accumulated Expenses rose 105.61% year-over-year to $586000.0 in Q2 2026; TTM through Jun 2026 was $586000.0, a 105.61% increase from a year earlier, with the FY2025 full-year figure at $287000.0, up 6.69% from the prior year.
- Other Accumulated Expenses was $586000.0 for Q2 2026 at NextPlat, up from $204000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $586000.0 in Q2 2026 and troughed at $6364.0 in Q2 2022.
- A 5-year average of $194232.1 and a median of $187500.0 in 2023 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses sank 71.72% in 2022 and soared 1506.03% in 2023, its largest moves.
- Over 5 years, Other Accumulated Expenses stood at $41000.0 in 2022, then surged by 356.1% to $187000.0 in 2023, then surged by 43.85% to $269000.0 in 2024, then grew by 6.69% to $287000.0 in 2025, then surged by 104.18% to $586000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $586000.0 (Q2 2026), $204000.0 (Q1 2026), and $287000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 586,000.00 |
| Mar 31, 2026 | 204,000.00 |
| Dec 31, 2025 | 287,000.00 |
| Sep 30, 2025 | 577,000.00 |
| Jun 30, 2025 | 285,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Dec 31, 2024 | 269,000.00 |
| Sep 30, 2024 | 158,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Mar 31, 2024 | 117,000.00 |
| Dec 31, 2023 | 187,000.00 |
| Sep 30, 2023 | 239,090.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 26,548.00 |
| Dec 31, 2022 | 41,000.00 |
| Sep 30, 2022 | 14,887.00 |
| Jun 30, 2022 | 6,364.00 |
| Mar 31, 2022 | 13,289.00 |
| Dec 31, 2021 | 40,305.00 |
| Sep 30, 2021 | 10,973.00 |